News | Proton Therapy | June 22, 2020

Orfit Aerial Couch Top for Proton Therapy Validated by Mevion Medical Systems

Mevion Medical Systems and Orfit Industries announced that the Aerial Couch Top is validated for use on the Mevion S250 Series Proton Therapy Systems.

June 22, 2020 —  Mevion Medical Systems and Orfit Industries announced that the Aerial Couch Top is validated for use on the Mevion S250 Series Proton Therapy Systems.

“Mevion is committed to providing customizable and complementary immobilization products to our customers and we are excited to partner with Orfit to add the Aerial Couch Top and accessories to our proton therapy systems,” said Ying Xiong, vice president of product management at Mevion Medical Systems.

The Aerial Couch Top combines precise and reproducible immobilization with homogeneity over the entire treatment area. With no rails or other obstructions below the extension, this recently US FDA cleared couch top minimizes the air gap, improving penumbra and plan quality. Aerial extensions are available for extracranial treatment and brain, head, and neck treatments when used with Orfit HP PRO masks. The use of 3-points single layer HP PRO masks can reduce target margins to 1 mm.

“The design of the Aerial is in line with the highest technical and safety standards, without being overly complex, so that it helps assure the best possible clinical outcome for patients. This couch top perfectly pairs with advanced proton therapy systems, such as MEVION S250i,” stated Emilie Cuypers, product manager radiation oncology at Orfit.

Together, we are pleased to make this entirely new couch top available as of September 2020 to current and future Mevion operated proton therapy centers.

For more information: www.mevion.com

Related Content

Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
News | Treatment Planning | September 15, 2020
September 15, 2020 — Varian announced it has received FDA 510(k) clearance for its Eclipse v16.1 treatment planning s
High-intensity focused ultrasound (HIFU), a technology used to treat localized prostate cancer, has shown adequate control of prostate cancer while avoiding major side effects of surgery or radiation therapy, according to a new study in The Journal of Urology, Official Journal of the American Urological Association

Getty Images

News | Prostate Cancer | September 08, 2020
September 8, 2020 — Approved by the US Food and Drug Administration (FDA) in 2015 for prostate tissue ablation, the h
the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...
Single-dose radiotherapy replaces need for extra hospital visits, with benefits for patient safety and well-being

Getty Images

News | Women's Health | August 20, 2020
August 20, 2020— For most women with early breast cancer
The results of an online questionnaire of 609 breast cancer survivors in the U.S. suggest that nearly half of patients experienced delays in care during the early weeks of the COVID-19 pandemic.

Getty Images

News | Coronavirus (COVID-19) | August 19, 2020
August 19, 2020 — The...
Smoking is strongly linked to lower use of cancer screening services by women, and more advanced disease once cancer is diagnosed, reveals research published in the online journal BMJ Open.

Getty Images

News | Lung Imaging | August 14, 2020
August 14, 2020 — Smoking is strongly linked to lower use of...
Rafael Rivero, M.D., Global Head of Medical Affairs at MSI, said: "The importance of MyoStrain cannot be understated because of the test's immense clinical value and ability to quantify intramyocardial dysfunction across 48 segments of the heart. In a six-heartbeat MRI scan, MyoStrain arms physicians with novel clinical information about a patient's heart health."
News | Cardiac Imaging | August 11, 2020
August 11, 2020 — Myocardial Solutions, Inc. and United Imaging, Inc.